New Diagnosis Type 2 Diabetes
Confirmed by A1c ≥6.5%, FPG ≥126, or 2h-OGTT ≥200
All Pathways
Family MedicineManagement
Type 2 Diabetes Initial Workup & Management (ADA 2025)
Type 2 Diabetes Initial Workup & Management (ADA 2025): New Diagnosis Type 2 Diabetes → Initial Evaluation → Cardiovascular/Renal Risk Assessment → High...
Pathway Overview
11 steps
Algorithm Steps
11 total
01Start 02Action Initial Evaluation
Comprehensive metabolic assessment
- A1c (confirms diagnosis, baseline)
- Lipid panel (CV risk)
- Comprehensive metabolic panel
- Urinalysis + urine albumin/creatinine
- Foot exam, fundoscopy referral
03Decision Cardiovascular/Renal Risk Assessment
Determines medication priority
- Established ASCVD?
- Heart failure present?
- CKD (eGFR <60 or albuminuria)?
- Multiple CV risk factors?
04Action High CV/Renal Risk
GLP-1 RA or SGLT2i priority
- Add GLP-1 RA (semaglutide, liraglutide) for ASCVD
- Add SGLT2i (empagliflozin, dapagliflozin) for HF/CKD
- Independent of A1c, add to metformin
- Both classes have proven CV/renal benefits
05Decision A1c Recheck at 3 Months
Assess response to therapy
- Target: <7% for most adults
- <6.5% if young, no hypoglycemia risk
- <8% if elderly, frail, limited life expectancy
06Outcome At A1c Goal
Continue current regimen, monitor every 3-6 months
07Action Add Second Agent
Intensify therapy if above goal
- Preferred: GLP-1 RA or SGLT2i
- Alternatives: DPP-4i, TZD, sulfonylurea
- Consider cost, side effects, patient preference
- Avoid SU + insulin (hypoglycemia risk)
- Path rejoins step 05Shared downstream outcome
08Action Add Third Agent or Insulin
Triple therapy or basal insulin
- If still above goal on 2 agents
- Consider basal insulin (start 10U or 0.1-0.2 U/kg)
- Titrate by 2U every 3 days to FPG goal
- Can add to GLP-1 RA + metformin
- Path rejoins step 05Shared downstream outcome
09Action Low CV Risk
Focus on glycemic control
- Start metformin 500mg BID
- Titrate to 1000mg BID over 1-2 months
- If A1c >9%, consider dual therapy upfront
- Lifestyle modification essential
- Path rejoins step 05Shared downstream outcome
10Action Complication Screening
Annual assessments
- Dilated eye exam annually
- Foot exam each visit
- BP goal <130/80
- Statin for ages 40-75
- UACR annually
11Action Lifestyle Interventions
Foundation of all therapy
- Medical nutrition therapy referral
- 150 min/week moderate activity
- Weight loss goal 5-10%
- Smoking cessation
- Diabetes self-management education
Guideline Source
ADA Standards of Care in Diabetes 2025
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not address Type 1 diabetes or LADA
- Insulin dosing requires individualization
- Renal dosing adjustments not detailed
- Does not address pediatric T2DM
- GLP-1 RA/SGLT2i contraindications require review
Contraindicated Populations
pediatricpregnancy
Applicable Regions
USAUEU
AU: RACGP guidelines largely align with ADA
EU: EASD/ADA consensus applies
US: Based on ADA 2025 Standards of Care
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Type 2 Diabetes Initial Workup & Management (ADA 2025)?
The Type 2 Diabetes Initial Workup & Management (ADA 2025) is a management clinical algorithm for Family Medicine. It provides a structured decision tree to guide clinical decision-making, based on ADA Standards of Care in Diabetes 2025.
What guideline is the Type 2 Diabetes Initial Workup & Management (ADA 2025) based on?
This algorithm is based on ADA Standards of Care in Diabetes 2025 (DOI: 10.2337/dc25-SINT).
What are the limitations of the Type 2 Diabetes Initial Workup & Management (ADA 2025)?
Known limitations include: Does not address Type 1 diabetes or LADA; Insulin dosing requires individualization; Renal dosing adjustments not detailed; Does not address pediatric T2DM; GLP-1 RA/SGLT2i contraindications require review. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Type 2 Diabetes Initial Workup & Management (ADA 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free